We are proud to have our portfolio company Nucleai and Bio-Techne presented compelling clinical trial data validating their cutting-edge, AI-powered spatial biology workflow. The data demonstrates the platform’s potential to successfully identify novel predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies. By combining Bio-Techne’s spatial biology technology with Nucleai’s advanced AI platform, this integrated workflow is significantly accelerating the validation and discovery of precision oncology insights, enabling more informed treatment decisions and advancing the standard of care.
Learn more here